DrugPatentWatch Database Preview
Drugs in Development Information for Defactinib
» See Plans and Pricing
What is the development status for investigational drug Defactinib?
Defactinib is an investigational drug.
There have been 19 clinical trials for Defactinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on April 30th 2020.
The most common disease conditions in clinical trials are Mesothelioma, Ovarian Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Verastem, Inc., Merck Sharp & Dohme Corp., and Washington University School of Medicine.
There are six US patents protecting this investigational drug and forty-seven international patents.
Summary for Defactinib
| US Patents | 6 |
| International Patents | 47 |
| US Patent Applications | 19 |
| WIPO Patent Applications | 82 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2020-04-30) |
| Vendors | 49 |
Recent Clinical Trials for Defactinib
| Title | Sponsor | Phase |
|---|---|---|
| Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma | Verastem, Inc. | Phase 2 |
| Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma | Thomas Jefferson University | Phase 2 |
| A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V or Other KRAS-Mutant Non-Small Cell Lung Cancer | Verastem, Inc. | Phase 2 |
Clinical Trial Summary for Defactinib
Top disease conditions for Defactinib
Top clinical trial sponsors for Defactinib
US Patents for Defactinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Defactinib | Start Trial | Methods and compositions for treating abnormal cell growth | Verastem, Inc. (Needham, MA) | Start Trial |
| Defactinib | Start Trial | Sulfonyl amide derivatives for the treatment of abnormal cell growth | Pfizer, Inc. (New York, NY) | Start Trial |
| Defactinib | Start Trial | Sulfonyl amide derivatives for the treatment of abnormal cell growth | Pfizer Inc (New York, NY) | Start Trial |
| Defactinib | Start Trial | Sulfonyl amide derivatives for the treatment of abnormal cell growth | Pfizer Inc (New York, NY) | Start Trial |
| Defactinib | Start Trial | Sulfonyl amide derivatives for the treatment of abnormal cell growth | Start Trial | |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Defactinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Defactinib | Denmark | DK3102232 | 2034-02-07 | Start Trial |
| Defactinib | European Patent Office | EP3102232 | 2034-02-07 | Start Trial |
| Defactinib | European Patent Office | EP3698790 | 2034-02-07 | Start Trial |
| Defactinib | Spain | ES2779975 | 2034-02-07 | Start Trial |
| Defactinib | Hong Kong | HK1232152 | 2034-02-07 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
